US bladder cancer market was valued at $2.4 billion in 2025 and is projected to reach $4.0 billion by 2035, growing at a CAGR of 5.5% during the forecast period (2026–2035). The US bladder cancer market is undergoing a structural shift driven by rising incidence, high recurrence rates, and the expanding role of immuno-oncology across non–muscle invasive and metastatic settings. Among a large prevalent patient pool requiring long-term surveillance and repeated intervention, therapeutic intensity has increased significantly over the past five years. Against this backdrop, combination therapy has emerged as the dominant development and commercialization model, reshaping competitive dynamics and treatment standards. Pharmaceutical innovators are increasingly advancing PD-1/PD-L1 inhibitors in combination with antibody-drug conjugates, chemotherapy, or targeted agents to improve response durability and progression-free survival. This strategy not only enhances clinical differentiation but also extends product life cycles and strengthens pricing power in a competitive oncology landscape. Combination regimens are becoming central in first-line and maintenance settings, supported by robust clinical trial pipelines and accelerated regulatory pathways. For instance, in March 2024, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer. The approval was based on results from the Phase 3 CheckMate-901 trial, in which the combination reduced the risk of death by 22% and improved median overall survival to 21.7 months compared to 18.9 months with chemotherapy alone. As payers prioritize value-based outcomes, combination approaches demonstrating superior efficacy are gaining faster uptake across academic and community oncology networks. Consequently, combination therapy is expected to remain the primary growth engine of the US bladder cancer market through the next decade.
Browse the full report description of “US Bladder Cancer Market Size, Share & Trends Analysis Report by Cancer Type (Transitional Cell Bladder Cancer/ Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types) By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (Ivp), and Other) By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Other), 2026–2035)” at https://www.omrglobal.com/industry-reports/us-bladder-cancer-market
Strategic Developments and Competitive Landscape in the US Bladder Cancer Market
Major players in the US bladder cancer market, including Merck & Co., Inc., Pfizer Inc., Bristol Myers Squibb Co., Eli Lilly and Company, and Incyte Corp., continue to focus on expanding immunotherapy indications and advancing novel targeted treatments across muscle-invasive and non-muscle invasive bladder cancer segments. Strategic collaborations, regulatory approvals, and late-stage clinical trials are strengthening competitive positioning and accelerating innovation within the market.
Market Coverage
Key questions addressed by the report.
UK Bladder Cancer Market Report Segment
Cancer Type
Diagnosis Method
By Therapy
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/us-bladder-cancer-market